Integrating RNA-Seq and Proteomics for Tumor Subtyping

Why integrate RNA and protein profiles?

RNA-sequencing and proteomics measure related but distinct parts of tumor biology. RNA abundance reflects transcripts; protein abundance reflects detected proteins after processes such as translation and protein turnover. A tumor group visible in both assays may therefore have a more coherent molecular interpretation than a group found in only one. But the assays differ in scale, feature coverage, noise, and biological meaning. Integration must balance those differences rather than simply append columns and assume each layer contributes fairly.

The goal here is to identify candidate tumor subgroups from matched RNA and protein profiles, then ask whether pathway-level signals are supported in both layers. A subgroup is a pattern in the measured cohort, not automatically a clinical subtype or a causal mechanism. The earlier material on matched tumor multi-omics establishes the cohort-level setting; this case focuses on joint structure and pathway interpretation.

Prepare the matched profiles before clustering

Each row must refer to the same tumor in both matrices, with the same row order. RNA counts require an appropriate normalization and usually a variance-stabilizing or log-scale transformation for clustering; raw counts are not directly comparable with protein intensities. Protein measurements likewise need a suitable transformation and normalization. Handle batch effects and missingness in ways appropriate to the design, and record which features were retained. A tumor with an unmatched assay cannot contribute to a complete-profile analysis without an explicit missing-data strategy.

For a transparent joint-distance approach, center and scale each retained feature within its assay so that a standardized feature has approximately mean zero and variance one across tumors. This does not make RNA and protein biologically identical: it puts their numerical contributions on a more comparable scale. Scaling can be sensitive to outliers, and it does not correct batch effects or unreliable measurements. Check distributions, sample clustering by technical batch, and feature-level quality before proceeding.

Let \(p_R\) and \(p_P\) be the numbers of retained RNA and protein features. For tumors \(i\) and \(j\), define a weighted squared distance:

Here \(Z^{(R)}\) and \(Z^{(P)}\) denote the standardized matrices. Equal weights, \(w_R=w_P=0.5\), are a defensible starting point when neither assay should dominate by design. The division by the number of features prevents an assay from gaining influence merely because it has more measured features. Weights still encode an analytic choice and should be varied in a sensitivity analysis.

From joint profiles to candidate subtypes

Apply a clustering method to the joint profiles or the distance matrix. For example, hierarchical clustering groups tumors according to a specified linkage rule, while k-means minimizes within-cluster squared distances around cluster means. These methods answer somewhat different geometric questions. K-means favors compact, roughly spherical groups in the chosen feature representation; hierarchical clustering depends on its distance and linkage choices. Neither method proves that discrete biological subtypes exist.

Choose the number of clusters using more than a visually appealing heat map. Consider stability under tumor resampling, reasonable changes in feature selection and assay weights, and whether the proposed groups are large enough to interpret. If a cluster disappears under modest perturbations, report it as uncertain rather than as a robust subtype. Examine whether clusters align with technical batches, collection sites, or other known design variables; a technical grouping can masquerade as biology.

Describe each candidate group using features and pathway patterns not defined solely by its cluster label. When clusters and their supporting features are discovered in the same data, apparent separation is optimistic. Resampling or held-out assessment can reveal instability, but a small cohort may not support a genuinely independent validation set. Report the exploratory status and the scope of the evidence.

Pathway-level assessment

A pathway can be examined by testing whether more of its genes than expected appear among features associated with a tumor group. For over-representation analysis, define the eligible gene universe before testing: it should consist of genes that could have been selected given the assay, filtering, and analysis. For RNA, this is not necessarily every annotated gene. Protein analysis may have a different universe because not every gene product is detectable. Map identifiers carefully and avoid counting multiple measurements of the same gene as independent genes.

If \(N\) genes are in the eligible universe, \(K\) belong to a pathway, \(n\) are in a selected gene list, and \(x\) are in both, then under the null of random selection of \(n\) genes from the universe, the overlap count \(X\) follows a hypergeometric distribution. The one-sided over-representation probability is \(P(X\geq x)\). This test assumes the universe and pathway membership are defined correctly; its simple null does not fully account for gene-gene correlation or unequal selection probabilities.

Over-representation is not the only option. A ranked-list analysis can use evidence across a full set of genes instead of imposing a selected-gene threshold, which may be useful when many genes show modest changes. A pathway score computed for each tumor is another option: it can summarize coordinated activity and be compared between candidate groups. These alternatives answer related but non-identical questions. State the method and its assumptions, and do not choose whichever method happens to give the strongest result.

Compare pathway patterns across RNA and protein

Assess the pathway separately in each assay, using the eligible universe and measurements for that layer. Then compare direction, membership, and consistency of the signal. A pathway enriched in both assays, with reasonably aligned gene-level directions, offers cross-layer support. A result in only one assay may reflect genuine biology, limited protein detection, measurement noise, or analysis choices. Lack of protein evidence is not automatically evidence that the RNA finding is false.

For pathway scores, compute a score for each tumor within each layer using a stated rule, such as the mean of standardized pathway features. Because measurements are matched by tumor, preserve that pairing when estimating uncertainty or comparing layers. A simple group contrast describes the pattern; inferential comparisons additionally require assumptions about independent tumors, the score distributions, and the sampling scheme. Do not treat genes within a pathway as independent biological replicates.

Alternatives, diagnostics, and limitations

Early integration, such as balanced concatenation, lets both assays contribute to the cluster assignments. A late-integration strategy clusters each assay separately and compares the resulting groups or pathway summaries; it can reveal whether each layer has its own structure but may not produce a single joint classification. Pathway-score integration emphasizes predefined biology and can reduce dimensionality, but it may miss signals outside the selected pathways. No strategy is universally best: the choice depends on whether the objective is a joint tumor grouping, a layer-specific pattern, or a focused pathway summary.

Check whether one assay dominates the joint distances by examining its realized contribution, not only its nominal weight. Repeat the analysis with plausible alternative weights, feature filters, and clustering choices. Inspect group sizes, assignment stability, batch alignment, and whether pathway findings are driven by a few highly influential features. In enrichment analysis, verify identifier mapping and the eligible universe; a universe that includes genes never measurable by the assay can produce misleading probabilities. Apply multiplicity correction across the tested pathways and report the number of tests.

A major limitation is that measured RNA and protein abundance are noisy, incomplete proxies for biological activity. Correlation among genes can make simple gene-count tests overconfident, and pathway databases are imperfect and overlapping. Standardization equalizes numerical scale, not measurement reliability or biological importance. The resulting subtypes are cohort-dependent candidates; clinical usefulness requires suitable further validation.